Details of the Drug Reposition

General Information of This Drug (ID: DML2CPW)

Drug Name
VAY736   DML2CPW
Drug Type
Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Sjogren syndrome DISUBX7H 4A43.20 Phase 2 [1]
Pemphigus vulgaris DISENR62 EB40 Phase 2 [2]
Rheumatoid arthritis DISTSB4J FA20 Phase 2 [3]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02137889) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)